Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 13/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.47 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22966559 | 0.84 | CDK4 (0.42) | CDK4CDK2CDK6MAPTLMNA | |
| SCHEMBL18806194 | 0.84 | ADORA2A (0.37) | PDCD1CD274CDK4FLT3CDK1 | |
| SCHEMBL18819904 | 0.84 | CDK4 (0.41) | PDCD1CD274CDK4FLT3MAPT | |
| SCHEMBL20249391 | 0.84 | CDK4 (0.42) | CDK4CDK1CDK2CDK7CDK9 | |
| SCHEMBL20255390 | 0.84 | CDK4 (0.43) | PDCD1CD274CDK4CDK1CDK2 | |
| SCHEMBL18806181 | 0.84 | CDK4 (0.40) | PDCD1CD274CDK4FLT3CDK1 | |
| SCHEMBL18806155 | 0.82 | CDK4 (0.44) | CDK4FLT3CDK2CDK6LMNA | |
| SCHEMBL18819902 | 0.81 | PDCD1 (0.52) | PDCD1CD274CDK4FLT3CDK1 | |
| SCHEMBL20249522 | 0.81 | CD274 (0.45) | PDCD1CD274CDK4CDK2CDK6 | |
| SCHEMBL21452407 | 0.80 | POLB (0.39) | PDCD1CD274CDK4CDK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PDCD1 344/4885CD274 1164/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.